What's Happening?
Latus Bio, a biotechnology company focused on gene therapies for central nervous system (CNS) and peripheral diseases, has appointed Bethany Mancilla as its Chief Business Officer. Mancilla brings over 25 years of experience in business development and corporate
strategy, having previously held senior roles at Capsida Biotherapeutics, Cue Biopharma, Kite Pharma, and Amgen. Her appointment comes as Latus Bio prepares to submit an Investigational New Drug (IND) application for LTS-201, a treatment for Huntington's disease, in the third quarter of 2026. Mancilla's expertise in securing high-value transactions and partnerships is expected to be instrumental as Latus Bio transitions into a clinical-stage company and expands its pipeline of gene therapies.
Why It's Important?
The appointment of Bethany Mancilla is significant for Latus Bio as it marks a strategic move to strengthen its leadership team during a critical phase of clinical development. Mancilla's track record in securing substantial non-dilutive funding and forming strategic partnerships will be crucial for Latus Bio's growth and ability to bring innovative therapies to market. Her leadership is expected to enhance the company's efforts in addressing unmet medical needs in CNS disorders, potentially benefiting patients with conditions like Huntington's disease. This development also underscores the growing importance of gene therapy in the biotechnology sector, highlighting Latus Bio's commitment to advancing precision medicine.
What's Next?
As Latus Bio moves forward with its clinical plans, the company is likely to focus on securing additional partnerships and funding to support its pipeline expansion. The submission of the IND for LTS-201 will be a key milestone, potentially leading to clinical trials that could validate the efficacy of their novel gene therapy approach. Stakeholders, including investors and patients, will be closely monitoring the progress of Latus Bio's clinical programs and any new collaborations that may arise under Mancilla's leadership.
